<DOC>
	<DOCNO>NCT02433184</DOCNO>
	<brief_summary>The main aim study determine whether TNFi institute first-line therapy early RA confers well outcome ( clinical , structural immunological ) compare delay TNFi start ; imply particular dominance TNF early disease , change role TNF disease duration hence , confirmation biological window opportunity .</brief_summary>
	<brief_title>Very Early Versus Delayed Etanercept Patients With RA</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>Male female patient age 18 80 year . Diagnosis rheumatoid arthritis ( new 2010 ACR/EULAR RA classification criterion ) . Symptom onset within precede 12 month . Patients active RA baseline : clinical evidence synovitis ( image evidence synovitis case uncertainty/subclinical disease ) hand and/or wrist joint evaluable ultrasound MRI , DAS28ESR &gt; 3.2 . Seropositivity anticitrullinated peptide antibody ( ACPA ) and/or rheumatoid factor . If ACPA rheumatoid factor negative , presence power Doppler least 1 joint ultrasound imaging . DMARDnaive ( exception previous exposure hydroxychloroquine indication RA ) . All male female subject biologically capable child must agree use reliable method contraception duration study 24 week end study period . Acceptable method contraception surgical sterilisation , oral , implantable injectable hormonal method , intrauterine device barrier contraceptive . Previous treatment DMARDs management RA . Intramuscular intraarticular ( nontarget joint ) corticosteroid within 28 day screen visit ; intraarticular steroid choose target joint within 12 week screen . Oral steroid great 10mg prednisolone daily , change oral steroid dose within 28 day study drug initiation baseline visit . Use ( include use require ) one NSAID , change NSAID change dose NSAID within 28 day baseline visit . Contraindications MRI ( e.g . pacemaker ) unable unwilling attend image assessment . In patient previous penetrate trauma eye , patient high risk previous metal foreign body injury eye ( e.g . weld ) , skull xray perform ; patient may include absence residual metal fragment xray . Pregnancy breastfeeding . Other contraindication TNFi determine local prescribe guideline physician discretion , include : Active infection , open leg ulcer , previously infect prosthetic joint ( unless completely remove ) , septic arthritis last year , HIV , Hepatitis B Hepatitis C carrier , previous malignancy within 10 year ( except basal cell carcinoma ) , severe heart failure ( New York Heart Association grade 3 ) , history demyelinate disease , uncontrolled diabetes , pulmonary fibrosis , bronchiectasis , previous PUVA therapy ( &gt; 1000 Joules ) , history TB evidence latent TB chest xray/TB test ( latter event , patient may include treated isoniazid pyridoxine one month start study 6 month whilst study treatment ) . History significant medical condition , include : Severe pulmonary disease , define require previous hospital admission supplemental oxygen . Active severe cardiovascular disease : uncontrolled hypertension , myocardial infarction within 12 month screen , unstable angina within 6 month screen . Other immunodeficiency disorder . Connective tissue disease , e.g . primary Sjogren 's syndrome , systemic sclerosis , systemic lupus erythematosus , polymyositis . Psoriasis . Renal impairment ( creatinine ≥ 175µmol/L ) . Blood disorder : neutropenia ( neutrophils &lt; 2.0 x 109/L ) , thrombocytopenia ( platelet &lt; 125 x 109/L ) , anaemia ( haemoglobin &lt; 8 g/dL ) . Abnormal liver function ( alanine transaminase , ALT &gt; 3 x upper limit normal ) . Planned surgery within study period expect require omission study medication 28 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Etanercept</keyword>
	<keyword>treat target</keyword>
	<keyword>Disease Modifying Antirheumatic Drugs ( DMARDs )</keyword>
</DOC>